These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28039694)

  • 41. A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.
    Wei H; Bera TK; Wayne AS; Xiang L; Colantonio S; Chertov O; Pastan I
    J Biol Chem; 2013 Apr; 288(17):12305-12. PubMed ID: 23486472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
    Castelletti D; Fracasso G; Righetti S; Tridente G; Schnell R; Engert A; Colombatti M
    Clin Exp Immunol; 2004 May; 136(2):365-72. PubMed ID: 15086403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
    Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK; Pastan I
    Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules.
    Onda M; Vincent JJ; Lee B; Pastan I
    Bioconjug Chem; 2003; 14(2):480-7. PubMed ID: 12643760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant toxins for the treatment of cancer.
    Kreitman RJ
    Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.
    Kennedy PE; Bera TK; Wang QC; Gallo M; Wagner W; Lewis MG; Berger EA; Pastan I
    J Leukoc Biol; 2006 Nov; 80(5):1175-82. PubMed ID: 16923920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotoxins and cancer therapy.
    Li Z; Yu T; Zhao P; Ma J
    Cell Mol Immunol; 2005 Apr; 2(2):106-12. PubMed ID: 16191416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
    Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
    J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.
    Oh S; Stish BJ; Sachdev D; Chen H; Dudek AZ; Vallera DA
    Clin Cancer Res; 2009 Oct; 15(19):6137-47. PubMed ID: 19789305
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant immunotoxins for the treatment of haematological malignancies.
    Kreitman RJ
    Expert Opin Biol Ther; 2004 Jul; 4(7):1115-28. PubMed ID: 15268678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.
    Luther N; Cheung NK; Souliopoulos EP; Karampelas I; Bassiri D; Edgar MA; Guo HF; Pastan I; Gutin PH; Souweidane MM
    Mol Cancer Ther; 2010 Apr; 9(4):1039-46. PubMed ID: 20371725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.
    Li Z; Mahesh SP; Shen DF; Liu B; Siu WO; Hwang FS; Wang QC; Chan CC; Pastan I; Nussenblatt RB
    Cancer Res; 2006 Nov; 66(21):10586-93. PubMed ID: 17079483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simultaneous elimination of T- and B-cell epitope by structure-based mutagenesis of single Glu80 residue within recombinant staphylokinase.
    He J; Xu R; Chen X; Jia K; Zhou X; Zhu K
    Acta Biochim Biophys Sin (Shanghai); 2010 Mar; 42(3):209-15. PubMed ID: 20213046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
    Mossoba ME; Onda M; Taylor J; Massey PR; Treadwell S; Sharon E; Hassan R; Pastan I; Fowler DH
    Clin Cancer Res; 2011 Jun; 17(11):3697-705. PubMed ID: 21521777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization.
    Benhar I; Brinkmann U; Webber KO; Pastan I
    Bioconjug Chem; 1994; 5(4):321-6. PubMed ID: 7948099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
    Weldon JE; Xiang L; Zhang J; Beers R; Walker DA; Onda M; Hassan R; Pastan I
    Mol Cancer Ther; 2013 Jan; 12(1):48-57. PubMed ID: 23136186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
    Mussai F; Campana D; Bhojwani D; Stetler-Stevenson M; Steinberg SM; Wayne AS; Pastan I
    Br J Haematol; 2010 Aug; 150(3):352-8. PubMed ID: 20528877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.
    Laroche Y; Heymans S; Capaert S; De Cock F; Demarsin E; Collen D
    Blood; 2000 Aug; 96(4):1425-32. PubMed ID: 10942387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.